Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab

A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Medicine Insights. Oncology 2015-01, Vol.9
Main Authors: Jennie Y. Law, Dong W. Kim, Ariel Sturgis, Harris V. Naina
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title Clinical Medicine Insights. Oncology
container_volume 9
creator Jennie Y. Law
Dong W. Kim
Ariel Sturgis
Harris V. Naina
description A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.
doi_str_mv 10.4137/CMO.S27142
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb0</doaj_id><sourcerecordid>oai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb0</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb03</originalsourceid><addsrcrecordid>eNqtjMGKwjAURcOAoIxu_IL3A3WSJrFmLTMoOCroPry2iY3TNpJGRL9-ivgJ3s3l3AOXkCmjM8F49rX83c0OacZE-kFGjGUqkVKoIZl03Zn24ZxSmY3IeuvbZOXL059rYXNvLpVvELyFWBk4xB6KCnqFsMfoTBvhGAxGU8LNxQq2GLF2j2uD-ZgMLNadmbz6k6x_vo_LVVJ6POtLcA2Gu_bo9HPw4aQxRFfURhcoURrLOLVK5Auu5oWVyKmQakFtTvk7v_4B7ilZ0Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab</title><source>Open Access: PubMed Central</source><source>SAGE Open Access</source><source>ProQuest - Publicly Available Content Database</source><creator>Jennie Y. Law ; Dong W. Kim ; Ariel Sturgis ; Harris V. Naina</creator><creatorcontrib>Jennie Y. Law ; Dong W. Kim ; Ariel Sturgis ; Harris V. Naina</creatorcontrib><description>A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.</description><identifier>EISSN: 1179-5549</identifier><identifier>DOI: 10.4137/CMO.S27142</identifier><language>eng</language><publisher>SAGE Publishing</publisher><ispartof>Clinical Medicine Insights. Oncology, 2015-01, Vol.9</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Jennie Y. Law</creatorcontrib><creatorcontrib>Dong W. Kim</creatorcontrib><creatorcontrib>Ariel Sturgis</creatorcontrib><creatorcontrib>Harris V. Naina</creatorcontrib><title>Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab</title><title>Clinical Medicine Insights. Oncology</title><description>A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.</description><issn>1179-5549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjMGKwjAURcOAoIxu_IL3A3WSJrFmLTMoOCroPry2iY3TNpJGRL9-ivgJ3s3l3AOXkCmjM8F49rX83c0OacZE-kFGjGUqkVKoIZl03Zn24ZxSmY3IeuvbZOXL059rYXNvLpVvELyFWBk4xB6KCnqFsMfoTBvhGAxGU8LNxQq2GLF2j2uD-ZgMLNadmbz6k6x_vo_LVVJ6POtLcA2Gu_bo9HPw4aQxRFfURhcoURrLOLVK5Auu5oWVyKmQakFtTvk7v_4B7ilZ0Q</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Jennie Y. Law</creator><creator>Dong W. Kim</creator><creator>Ariel Sturgis</creator><creator>Harris V. Naina</creator><general>SAGE Publishing</general><scope>DOA</scope></search><sort><creationdate>20150101</creationdate><title>Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab</title><author>Jennie Y. Law ; Dong W. Kim ; Ariel Sturgis ; Harris V. Naina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jennie Y. Law</creatorcontrib><creatorcontrib>Dong W. Kim</creatorcontrib><creatorcontrib>Ariel Sturgis</creatorcontrib><creatorcontrib>Harris V. Naina</creatorcontrib><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Clinical Medicine Insights. Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jennie Y. Law</au><au>Dong W. Kim</au><au>Ariel Sturgis</au><au>Harris V. Naina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab</atitle><jtitle>Clinical Medicine Insights. Oncology</jtitle><date>2015-01-01</date><risdate>2015</risdate><volume>9</volume><eissn>1179-5549</eissn><abstract>A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.</abstract><pub>SAGE Publishing</pub><doi>10.4137/CMO.S27142</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1179-5549
ispartof Clinical Medicine Insights. Oncology, 2015-01, Vol.9
issn 1179-5549
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb0
source Open Access: PubMed Central; SAGE Open Access; ProQuest - Publicly Available Content Database
title Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A37%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-Hodgkin%20Lymphoma%20of%20the%20Stomach%20in%20a%20Patient%20Treated%20with%20Natalizumab&rft.jtitle=Clinical%20Medicine%20Insights.%20Oncology&rft.au=Jennie%20Y.%20Law&rft.date=2015-01-01&rft.volume=9&rft.eissn=1179-5549&rft_id=info:doi/10.4137/CMO.S27142&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb0%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_ca5a5ef130f94b8396cf5a3045980fb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true